The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
The gut microbiome develops into its adult-like state throughout a child's first five years, but certain important taxa aren't acquired until later.
Fresh off a name change, the company last week introduced a monitoring platform for new SARS-CoV-2 variants that alerts diagnostic test makers to potential problems.
Investigators identified natural killer cell-related expression signatures in blood samples from children who later developed type 1 diabetes or islet autoimmunity.
The study's finding suggest that over-stimulation of the complement pathway along with non-specific targeting of lung tissue contribute to death from the virus.
Sanjay Padhi has joined Tag.bio as executive VP and chief technologist. He comes to the San Francisco-based data analytics startup from Amazon Web Services, where he was head of AWS research. Prior to that, he was a scientist at CERN. Padhi holds a PhD in high energy physics from McGill University.
The companies will integrate their respective technologies into a platform for clinical genetics services, including test ordering and virtual counseling.
More than a dozen countries issue a statement expressing concerns about the World Health Organization report on the origins of the COVID-19 pandemic, Reuters reports.
In Genome Biology this week: DNA methylation features found among neurodegenerative disorders, analysis of somatic variants in the brain, and more.
Tempus has launched an amplicon-based, high-throughput next-generation sequencing assay for the detection of SARS-CoV-2 virus mutations. The research-use-only assay includes primers designed to detect mutations and to characterize SARS-CoV-2 RNA.
Analyst Max Masucci told investors he believes the stock is worth owning now, regardless of uncertainty surrounding Illumina's plans to acquire Grail.
The company is planning to commercialize its cancer early detection technology initially in lung cancer and is working with NYU researchers to explore future expansions.
Agilent will supply a custom-made SurePrint G3CGH Microarray for Oxford's newly launched Explorer Array Kit, which will include OBD's 3D Genome Probes.
The FDA identified molecular tests from Mesa Biotech, Applied DNA Sciences, Thermo Fisher Scientific, and Cepheid that could be affected by certain mutations.
The Taiwan-based startup aims to publish data showing the instrument's prognostic value in colorectal cancer, as well as launch a new version, by this summer.
South San Francisco-based digital health firm Genome Medical has made appointments to its management team and board of directors.
Brandon Poe has become the company's CFO. Previously, he was VP of finance at Illumina, and before that, CFO of medical device firm Sotera Wireless. He holds an MBA from the University of Chicago Booth School of Business and a bachelor's degree from Bucknell University.
Marco Barcella has been appointed as Genome Medical's chief product officer. Most recently, he held strategic product positions at Tiatros and at IBM Watson Health. He holds an MBA from the NYU Stern School of Business and a master of science degree from the University of Virginia.
Russell Glass has joined the firm as an independent director. He is the CEO of on-demand mental health company Ginger. Prior to that, he was the founder and CEO of Bizo, a B2B marketing and data firm that was sold to LinkedIn in 2014, which he then joined.
Menarini Silicon Biosystems has launched its CellSearch Circulating Multiple Myeloma Cells (CMMS) assay. The firm said the assay captures and enumerates CMMCs from peripheral blood samples. Menarini believes the assay offers significant standardization and sensitivity to monitor and understand multiple myeloma.
CareDx has appointed Titte Srinivas as vice president of digital development and clinical integration, Steven Stone as VP of KidneyCare, Dustin Leach as VP of customer experience, and Martyn Edney as senior VP and head of human resources.
Srinivas is a transplant nephrologist who joins CareDx from University Hospitals in Cleveland, where he served as the chief of the division of nephrology and hypertension and Peter B. DeOreo Chair in Nephrology and Dialysis. Stone joins CareDx from from Myriad Genetics, where he served as VP of cancer genomics and developed products for personalized medicine in oncology. Leach joins CareDx from Teva Pharmaceuticals, where he most recently served as senior director of patient services – program development. Edney joins CareDx from Iqvia, where he served as VP of HR for the US and Canada.
The company also announced that it has promoted Marica Grskovic to VP of cell transplant therapy, and Jere Ramsey-Lester to VP of HR.
Grskovic joined CareDx nine years ago and has played a role in overseeing the design and development of the company's transplant diagnostic tests. Ramsey-Lester has been with CareDx since 2019, and has served as interim head of HR for the past year. She has held leadership positions in human resources at TreeHouse Foods, ConAgra Foods, and Fiserv.
Pregnancy test firm Sera Prognostics has appointed Robert Harrison as chief information officer. For more than three decades, Harrison has served in senior leadership positions of both public and private companies. Most recently, he served as officer of Myriad Genetics' chief information office. With Myriad Genetics, he directed the information technology integration of four strategic acquisitions and helped facilitate its international business expansion over the past decade. Harrison is a member of the Association for Information Management Utah CIO Council and is a long-standing board member of the Utah Technology Council.
Researchers screened nine orthologs that had not been tried in plants before and identified six that possessed high editing activity in rice.
Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.